Alnylam's Shares Plunge 0.57% on Sept. 12 as Trading Volume Slumps to $300M Ranking 331st in U.S. Equities

. 12, 2025, , . , indicating reduced liquidity amid mixed investor sentiment.

Analysts noted limited catalysts for the stock’s performance, as recent developments centered on regulatory and operational updates. A key focus remained on the company’s pipeline advancements, including progress in gene-silencing therapies for rare diseases. However, no major clinical or partnership announcements were reported to drive significant price movement.

Market participants observed that the decline in volume contrasted with Alnylam’s typically high trading activity, suggesting temporary profit-taking or strategic position adjustments. The stock’s muted response to broader market trends underscored its dependence on sector-specific developments rather than macroeconomic factors.

To deliver a precise, trade-grade back-test, I need to lock-in a few practical details that aren’t fully specified yet: 1. Universe definition • Should we rank all U.S. common stocks (NYSE + NASDAQ + AMEX), or some narrower set (e.g., S&P 1500, Russell 3000, etc.)? • Any exclusions (penny stocks, ADRs, ETFs, preferreds)? 2. , ? , , ? • Equal-weight across the 500 names each rebalance? 3. Frictions • Apply transaction costs? (If so, a round-trip cost assumption is needed—e.g., . Benchmark / metrics • Any specific benchmark (e.g., ? Once we firm these up, I’ll generate the data-retrieval plan, pull the volume data, build daily portfolios, . Please let me know your preferences and I’ll proceed.